Swedish business magazine “Affärsvärlden” issues an apology to Oasmia

April 2 2012
Julian Aleksov, CEO of Oasmia and Bo Cederstrand, former Chairman of the Board of the company, have received full redress as the weekly business magazine Affärsvärlden (“Business World”) has apologised and withdrawn its accusations against them. This has happened after Affärsvärlden was sued by Mr Aleksov and Mr Cederstrand for serious libel. Affärsvärlden found, after reviewing the underlying facts, that there were no grounds for the conclusions that were drawn and has therefore apologised to Mr Aleksov and Mr Cederstrand.
Further reading »

Paccal Vet® update on the European Regulatory process

March 9 2012
Oasmia Pharmaceutical AB will address the European Medicines Agency’s (EMA) concern of the benefit to risk assessment regarding Paccal® Vet. Therefore Oasmia has decided following formal procedure; to withdraw the application for marketing authorization for Paccal® Vet from the European Medicines Agency (EMA) and to re-submit the application with additional, complementary data for final approval of Paccal® Vet. The withdrawal of the European application does not affect the on-going approval process for Paccal® Vet in the USA.
Further reading »

Article about Paccal Vet in Journal of Veterinary Internal Medicine

March 8 2012
A new scientifc article shows the results from the Phase III-study with Paccal® Vet. The results show that Paccal® Vet is significantly better compared to Lomustine and that Paccal Vet can meet a fill a substantial need within veterinary medicine.
Further reading »